Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2017 August;58(4) > The Journal of Cardiovascular Surgery 2017 August;58(4):518-27

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  RECENT DEVELOPMENTS IN THE MANAGEMENT OF IN-STENT RESTENOSIS 

The Journal of Cardiovascular Surgery 2017 August;58(4):518-27

DOI: 10.23736/S0021-9509.17.09946-3

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Optical coherence tomography: guided therapy of in-stent restenosis for peripheral arterial disease

Michael K., LICHTENBERG 1 , Jeffrey G., CARR 2, Jaafer A. GOLZAR 3

1 Vascular Centre Arnsberg Clinic, Arnsberg, Germany; 2 Cardiovascular Associates of East Texas, Tyler, TX, USA; 3 Advocate Health Care, Oak Lown, IL, USA


PDF


Approximately 27 million people in Europe and North America currently have peripheral arterial disease (PAD). The endovascular treatment of stenosis or blocked peripheral arteries in PAD include percutaneous transluminal angioplasty with or without a drug coated balloon (DCB), atherectomy (rotational, directional, orbital or laser), and stenting. The development of next generation peripheral stents and drug-coated stents have led to the improved treatment of complex superficial femoral artery (SFA) lesions, and consequently increased their usage. Additionally, the technologies developed for PAD intervention have further improved the overall adoption of endovascular procedures leading to increased utilization of stents to address procedural dissections (bailout stenting), as support scaffolding for complex lesions, and to prevent preventing elastic recoil post balloon angioplasty. For example, bail-out stenting after DCB angioplasty has been reported to be as high as 40% in long lesions and as high as 46% in chronic total occlusions lesions. In total, approximately 200,000 stents are placed annually in the femoral and popliteal arteries in PAD patients in the USA, with 30% to 40% of these stents expected to develop in-stent restenosis within 2-3 years of implantation. Accordingly, the treatment of in-stent restenosis (ISR) remains a substantial healthcare burden. Few technologies reported on improved ISR patency rates as compared to PTA treatment alone, including drug-eluting stents and balloons, laser atherectomy or covered stents. However, the reported longer-term patency for ISR remains suboptimal creating a cyclical treatment pattern that burdens patients and providers. In this review, we present the rational and clinical evidence for utilizing OCT-guided therapies for the treatment of ISR for PAD.


KEY WORDS: Angioplasty, balloon - Peripheral arterial disease - Tomography, optical coherence

top of page